VivoSeq
Oncology

CRC (colorectal Cancer)

3

Pipeline Programs↗

4

Active Trials↗

3

Companies Involved↗

CRC (Colorectal Cancer) is an early-stage landscape with 3 programs across 3 companies. The most active players are Incyte, Eli Lilly, AstraZeneca. 3 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

11/100

Mech. Concentration

100/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Incyte logo

Incyte

1 program

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3AstraZeneca logo

AstraZeneca

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 33

INCA33890

Incyte

Bevacizumab

Bio-Thera Solutions

FOLFOX

AstraZeneca

Approved
No programs

Analysis

Modality Breakdown

67%

Small molecule

2 of 3 classified programs — the dominant modality here.

33%ALL OTHERSMonoclonal antibody133%

Small molecule leads; the ring shows all 3 classified programs, each share of the total. Modality classified for 75% of 4 pipeline programs.

Analysis

Trial Status

4

clinical trials

Recruiting3 · 75%
Not yet recruiting1 · 25%

Clinical Trials

Trial Activity

Development of a cfDNA 5mC/5hmC-based Epigenetic Biomarker Panel to Predict Chemotherapy Efficacy in Metastatic Colorectal Cancer
Recruiting·CCity of Hope Medical Center·N/A·NCT07224815·600 enrolled
Development of a cfDNA 5mC/5hmC-based Epigenetic Biomarker Panel to Identify Determinants of Response In VEGF/EGFR-targeted Therapy for Metastatic Colorectal Cancer
Recruiting·CCity of Hope Medical Center·N/A·NCT07224841·500 enrolled
A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Recruiting·Incyte logoIncyte·Phase 3·NCT07284849·700 enrolled
Monocentric Retrospective and Prospective Observational Study of Patients With Colorectal Cancer
Not yet recruiting·IIRCCS San Raffaele·N/A·NCT07663162·2,000 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)